These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10665778)

  • 1. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.
    Yan J; Vetvicka V; Xia Y; Hanikýrová M; Mayadas TN; Ross GD
    Immunopharmacology; 2000 Jan; 46(1):39-54. PubMed ID: 10665778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
    Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
    J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage cytoskeleton association with CR3 and CR4 regulates receptor mobility and phagocytosis of iC3b-opsonized erythrocytes.
    Ross GD; Reed W; Dalzell JG; Becker SE; Hogg N
    J Leukoc Biol; 1992 Feb; 51(2):109-17. PubMed ID: 1358992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
    Vetvicka V; Thornton BP; Ross GD
    J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
    Thornton BP; Vĕtvicka V; Pitman M; Goldman RC; Ross GD
    J Immunol; 1996 Feb; 156(3):1235-46. PubMed ID: 8558003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3.
    Myones BL; Dalzell JG; Hogg N; Ross GD
    J Clin Invest; 1988 Aug; 82(2):640-51. PubMed ID: 2969921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast.
    Cain JA; Newman SL; Ross GD
    Complement; 1987; 4(2):75-86. PubMed ID: 3040333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
    Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
    J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes.
    Lukácsi S; Nagy-Baló Z; Erdei A; Sándor N; Bajtay Z
    Immunol Lett; 2017 Sep; 189():64-72. PubMed ID: 28554712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
    Vetvicka V; Thornton BP; Wieman TJ; Ross GD
    J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury.
    Cramer DE; Allendorf DJ; Baran JT; Hansen R; Marroquin J; Li B; Ratajczak J; Ratajczak MZ; Yan J
    Blood; 2006 Jan; 107(2):835-40. PubMed ID: 16179370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes.
    Elstad MR; Parker CJ; Cowley FS; Wilcox LA; McIntyre TM; Prescott SM; Zimmerman GA
    J Immunol; 1994 Jan; 152(1):220-30. PubMed ID: 7902855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissimilar and similar functional properties of complement receptor-3 in microglia and macrophages in combating yeast pathogens by phagocytosis.
    Hadas S; Reichert F; Rotshenker S
    Glia; 2010 May; 58(7):823-30. PubMed ID: 20091776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans.
    Taborda CP; Casadevall A
    Immunity; 2002 Jun; 16(6):791-802. PubMed ID: 12121661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles.
    Fällman M; Andersson R; Andersson T
    J Immunol; 1993 Jul; 151(1):330-8. PubMed ID: 8326130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement receptor type three-dependent degradation of opsonized erythrocytes by mouse macrophages.
    Rothlein R; Springer TA
    J Immunol; 1985 Oct; 135(4):2668-72. PubMed ID: 3897377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of membrane complement receptor type three (CR3) for beta-glucans.
    Ross GD; Cain JA; Myones BL; Newman SL; Lachmann PJ
    Complement; 1987; 4(2):61-74. PubMed ID: 3040332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation of CR1 (CD35), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in membranoproliferative glomerulonephritis type I.
    Soma J; Saito T; Seino J; Sato H; Ootaka T; Yusa A; Abe K
    Clin Exp Immunol; 1995 May; 100(2):269-76. PubMed ID: 7743666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.